ArticleACS infectious diseases2022
Identification of β-Lactams Active against
Abstract read
In one paragraph
Article in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Synthesis of 4-Aminoindole-Containing Cephalosporin Prodrugs and Their Biological Activity againstACS infectious diseases · 2026Article
- A Comprehensive Review of Genetic Mechanisms ofInfection and drug resistance · 2026Review
- Targeting mycobacterial transpeptidases: evaluating the roles of Ldt and PBP inhibition in suppressingAntimicrobial agents and chemotherapy · 2025Article
- Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2025Article
- Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.bioRxiv : the preprint server for biology · 2024Article
- Molecular and microbiological methods for the identification of nonreplicating Mycobacterium tuberculosis.PLoS pathogens · 2024Review
- A pairwise approach to revitalize β-lactams for the treatment of TB.Antimicrobial agents and chemotherapy · 2024Article
- Redirecting raltitrexed from cancer cell thymidylate synthase toScience advances · 2024Article
- Utilization of Existing Human Kinase Inhibitors as Scaffolds in the Development of New Antimicrobials.Antibiotics (Basel, Switzerland) · 2023Review
- Antibiotics in the clinical pipeline as of December 2022.The Journal of antibiotics · 2023Review
- Mutations inmBio · 2023Article
- Structural insights into RNase J that plays an essential role in Mycobacterium tuberculosis RNA metabolism.Nature communications · 2023Article
- Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease.Antimicrobial agents and chemotherapy · 2022Article
- HowFrontiers in cellular and infection microbiology · 2022Review
- "Upcycling" known molecules and targets for drug-resistant TB.Frontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors.
Ben GoldDepartment of Microbiology & Immunology, Weill Cornell Medicine, 413 East 69th Street, New York, New York 10021, United States.ORCID 0000-0002-9562-8241
Jun ZhangDepartment of Microbiology & Immunology, Weill Cornell Medicine, 413 East 69th Street, New York, New York 10021, United States.
Landys Lopez QuezadaDepartment of Microbiology & Immunology, Weill Cornell Medicine, 413 East 69th Street, New York, New York 10021, United States.
Julia RobertsDepartment of Microbiology & Immunology, Weill Cornell Medicine, 413 East 69th Street, New York, New York 10021, United States.
Yan LingDepartment of Microbiology & Immunology, Weill Cornell Medicine, 413 East 69th Street, New York, New York 10021, United States.
Madeleine WoodDepartment of Microbiology & Immunology, Weill Cornell Medicine, 413 East 69th Street, New York, New York 10021, United States.
Wasima ShinwariDepartment of Microbiology & Immunology, Weill Cornell Medicine, 413 East 69th Street, New York, New York 10021, United States.
Laurent GoullieuxSanofi, Infectious Diseases Therapeutic Area, 69280 Marcy l'Étoile, France.
Christine RoubertSanofi, Infectious Diseases Therapeutic Area, 69280 Marcy l'Étoile, France.
Laurent FraisseSanofi, Infectious Diseases Therapeutic Area, 69280 Marcy l'Étoile, France.
Eric BacquéSanofi, Infectious Diseases Therapeutic Area, 69280 Marcy l'Étoile, France.
Sophie LagrangeSanofi, Infectious Diseases Therapeutic Area, 69280 Marcy l'Étoile, France.
Bruno Filoche-RomméSanofi, Integrated Drug Discovery, 94400 Vitry sur Seine, France.
Michal ViethLilly Biotechnology Center, Eli Lilly and Company, 10290 Campus Point Dr, San Diego, California 92121, United States.
Philip A HipskindLilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
Louis N JungheimYourEncore, 20 North Meridian Street, Indianapolis, Indiana 46204, United States.
Jeffrey AubéDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Sarah M ScarryDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Stacey L McDonaldDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Kelin LiDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Andrew PerkowskiDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Quyen NguyenDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Véronique DartoisPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey 07103, United States.ORCID 0000-0001-9470-5009
Matthew ZimmermanPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey 07103, United States.
David B OlsenMerck & Co., Inc., Infectious Diseases, 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States.
Katherine YoungMerck & Co., Inc., Infectious Diseases, 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States.
Shilah BonnettTB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, Washington 98102, United States.
Douglas JoerssTB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, Washington 98102, United States.
Tanya ParishTB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, Washington 98102, United States.ORCID 0000-0001-7507-0423
Helena I BoshoffTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Bethesda, Maryland 20892, United States.ORCID 0000-0002-4333-206X
Kriti AroraTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Bethesda, Maryland 20892, United States.
Clifton E BarryTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Bethesda, Maryland 20892, United States.
Laura GuijarroGlobal Health Pharma R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain.
Sara AncaGlobal Health Pharma R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain.
Joaquín RullasGlobal Health Pharma R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain.
Beatriz Rodríguez-SalgueroGlobal Health Pharma R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain.
Maria S Martínez-MartínezGlobal Health Pharma R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain.
Esther Porras-De FranciscoGlobal Health Pharma R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain.
Monica CachoGlobal Health Pharma R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain.ORCID 0000-0001-6270-5370
David Barros-AguirreGlobal Health Pharma R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain.ORCID 0000-0002-4099-0438
Paul SmithIndependent Consultant, Global Health Pharma R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain.ORCID 0000-0002-0146-1410
Steven J BerthelPanorama Global, 2101 4th Avenue, Suite 2100, Seattle, Washington 98121, United States.
Carl NathanDepartment of Microbiology & Immunology, Weill Cornell Medicine, 413 East 69th Street, New York, New York 10021, United States.
Robert H BatesGlobal Health Pharma R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain.ORCID 0000-0003-1926-8114
Funding
Viable but Nonculturable MtbU19AI111143 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI GLICKMAN, MICHAEL S, NATHAN, CARL FRANCIS · 2014 to 2020
$48.6MDevelopment Of New Chemotherapeutics For TuberculosisZIAAI000693 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARRY, CLIFTON · 2009 to 2025
$20.1MA QTRAP 6500 LC-MS/MS System from SCIEX for high accuracy drug content analysisS10OD023524 · OD · RBHS-NEW JERSEY MEDICAL SCHOOL · PI DARTOIS, VERONIQUE · 2017 to 2017
$526kNIAID NIH HHS U19 AI111143NIH HHS S10 OD023524
Abstract
Rising antimicrobial resistance challenges our ability to combat bacterial infections. The problem is acute for tuberculosis (TB), the leading cause of death from infection before COVID-19. Here, we developed a framework for multiple pharmaceutical companies to share proprietary information and compounds with multiple laboratories in the academic and government sectors for a broad examination of the ability of β-lactams to kill
Indexed as
COVID-19Mycobacterium tuberculosisAnimalsbeta-LactamsDrug IndustryMiceSARS-CoV-2Universitiesbeta-Lactamsclavulanateconsortiumhigh-throughput screeningMycobacterium tuberculosistuberculosisβ-lactam
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.